On October 21, 2020 Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, reported that it will host an investor webcast on Oct. 28, 2020, at 4:30 p.m. Eastern time, to highlight the planned launch of the ConfirmDx-Melanoma test, which will be commercially available in the fourth quarter of 2020 (Press release, Castle Biosciences, OCT 21, 2020, View Source [SID1234568742]). ConfirmDx-Melanoma is designed for use in patients with difficult-to-diagnose suspicious pigmented (melanocytic), lesions.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Castle’s ConfirmDx-Melanoma test is designed to aid dermatopathologists in characterizing difficult-to-diagnose pigmented lesions. Of the 2 million suspicious pigmented lesions biopsied annually in the U.S., Castle estimates that approximately 300,000 of those cannot be confidently classified as either benign or malignant through traditional histopathology methods. ConfirmDx-Melanoma classifies these lesions as: benign (gene expression profile suggestive of benign neoplasm); intermediate-risk (gene expression profile cannot exclude malignancy); or malignant (gene expression profile suggestive of malignant melanoma). Interpreted in the context of other clinical, laboratory and histopathologic information, ConfirmDx-Melanoma is designed to add diagnostic clarity and confidence for dermatopathologists, while helping dermatologists better understand the clinical implications for more informed patient care.
Conference call and webcast details can be found below:
Title:
Castle Biosciences ConfirmDx-Melanoma Investor Webcast
Date:
October 28, 2020
Time:
4:30 p.m. ET
Dial-in:
US/Canada Participant Toll-Free Dial-in number: (877) 282-2581
US/Canada Participant International Dial-in number: (470) 495-9137
Conference ID:
4091207
The webcast will include Sarah I. Estrada, M.D., FACP, laboratory director, Affiliated Dermatology, as a guest speaker. There will be a brief Question & Answer session following management commentary.
A live webcast of the conference call can be accessed here View Source or via the webcast link on the Investor Relations page of the Company’s website (www.castlebiosciences.com). Please access the webcast at least 10 minutes before the conference call start time. An archive of the webcast will be available on the Company’s website until Nov.18, 2020.
About Suspicious Pigmented Lesions
In the U.S., approximately 2 million skin biopsies of pigmented or melanocytic lesions are performed annually, leading to the diagnosis of an estimated 130,000 invasive melanoma cases and more than 96,000 in situ melanoma cases. These biopsies are typically pigmented lesions for which the healthcare provider suspects melanoma. The majority of these biopsies receive a definitive diagnosis by the dermatopathologist using traditional microscopic analyses. However, approximately 300,000 biopsies are considered difficult-to-diagnose using this traditional method and require additional testing to clarify the likelihood that this lesion is benign or malignant. And though there are several options for further testing, Castle believes there is a need for improvements in objective tests to resolve this diagnostic dilemma.